Universitätsklinikum Heidelberg Nationales Centrum für Tumorerkrankungen (NCT Heidelberg)
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Roderburg, Christoph
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
TRITICC, NCT04059562: Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma

Completed
2
28
Europe
Combination of Lonsurf® and Irinotecan
Heinrich-Heine University, Duesseldorf, Servier
Cholangiocarcinoma
01/24
01/24
NCT06440993: Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Recruiting
2
42
Europe
Gemcitabine, Cisplatin, Durvalumab, ID-RFA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Universitätsklinikum Düsseldorf, Germany, Universitätsklinikum Köln, Germany, AstraZeneca
Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
01/27
04/28
NCT06680622: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Not yet recruiting
2
126
Europe
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich
Metastatic Gastro-esophageal Adenocarcinoma
09/27
03/28
FUTURE, NCT06722183: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Not yet recruiting
2
33
Europe
Futibatinib orally administered, Tislelizumab (i.v. 200mg)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler
Colorectal Cancer
06/27
06/27
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29

Download Options